Found: 16
Select item for more details and to access through your institution.
Real-world effectiveness of dimethyl fumarate versus fingolimod in a cohort of patients with multiple sclerosis using standardized, quantitative outcome metrics.
- Published in:
- Multiple Sclerosis Journal - Experimental, Translational & Clinical, 2022, p. 1, doi. 10.1177/20552173211069852
- By:
- Publication type:
- Article
Impact of natalizumab on quality of life in a real-world cohort of patients with multiple sclerosis: Results from MS PATHS.
- Published in:
- Multiple Sclerosis Journal - Experimental, Translational & Clinical, 2021, p. 1, doi. 10.1177/20552173211004634
- By:
- Publication type:
- Article
Impact of natalizumab on quality of life in a real-world cohort of patients with multiple sclerosis: Results from MS PATHS.
- Published in:
- Multiple Sclerosis Journal - Experimental, Translational & Clinical, 2021, v. 7, n. 2, p. 1, doi. 10.1177/20552173211004634
- By:
- Publication type:
- Article
Effect of tobacco use on disease activity and DMT discontinuation in multiple sclerosis patients treated with dimethyl fumarate or fingolimod.
- Published in:
- Multiple Sclerosis Journal - Experimental, Translational & Clinical, 2020, p. 1, doi. 10.1177/2055217320959815
- By:
- Publication type:
- Article
Effect of tobacco use on disease activity and DMT discontinuation in multiple sclerosis patients treated with dimethyl fumarate or fingolimod.
- Published in:
- Multiple Sclerosis Journal - Experimental, Translational & Clinical, 2020, v. 6, n. 4, p. 1, doi. 10.1177/2055217320959815
- By:
- Publication type:
- Article
Duration of natalizumab therapy and reasons for discontinuation in a multiple sclerosis population.
- Published in:
- Multiple Sclerosis Journal - Experimental, Translational & Clinical, 2020, v. 6, n. 1, p. N.PAG, doi. 10.1177/2055217320902488
- By:
- Publication type:
- Article
Immunoglobulin G immune response to SARS-CoV-2 vaccination in people living with multiple sclerosis within Multiple Sclerosis Partners Advancing Technology and Health Solutions.
- Published in:
- Multiple Sclerosis Journal, 2022, v. 28, n. 7, p. 1131, doi. 10.1177/13524585211061343
- By:
- Publication type:
- Article
Patient-Focused Treatment Decisions in the Management of Multiple Sclerosis.
- Published in:
- Journal of Managed Care Medicine, 2022, v. 25, n. 3, p. 20
- By:
- Publication type:
- Article
Associations of sNfL with clinico‐radiological measures in a large MS population.
- Published in:
- Annals of Clinical & Translational Neurology, 2023, v. 10, n. 1, p. 84, doi. 10.1002/acn3.51704
- By:
- Publication type:
- Article
Disease activity outcomes with different washout periods after switching from natalizumab to an alternative disease-modifying therapy.
- Published in:
- Journal of Neurology, 2020, v. 267, n. 8, p. 2214, doi. 10.1007/s00415-020-09816-1
- By:
- Publication type:
- Article
Harnessing Real-World Data to Inform Decision-Making: Multiple Sclerosis Partners Advancing Technology and Health Solutions (MS PATHS).
- Published in:
- Frontiers in Neurology, 2020, p. N.PAG, doi. 10.3389/fneur.2020.00632
- By:
- Publication type:
- Article
Diversity, Equity, and Inclusion in the Multiple Sclerosis Community: A Call to Action.
- Published in:
- International Journal of MS Care, 2023, v. 25, n. 5, p. 199, doi. 10.7224/1537-2073.2023-039
- By:
- Publication type:
- Article
Real-World Findings of Usability and Usefulness of Multiple Sclerosis Progression Discussion Tool: A Physician-Completed Digital Tool to Evaluate Early Signs of Disease Progression.
- Published in:
- International Journal of MS Care, 2020, v. 22, n. S2, p. 86
- By:
- Publication type:
- Article
(DXT11) The Implications of Suboptimal Treatment Outcomes with Disease-Modifying Drugs in Employees with Multiple Sclerosis.
- Published in:
- International Journal of MS Care, 2020, v. 22, n. S2, p. 19
- By:
- Publication type:
- Article
(RHI03) Creating a Yoga Program as Part of a Comprehensive Multiple Sclerosis Care Model.
- Published in:
- International Journal of MS Care, 2020, v. 22, n. S2, p. 8
- By:
- Publication type:
- Article
(DMT01) Comparative Effectiveness of Switching from Natalizumab to a Moderate-Versus High-Efficacy Disease-Modifying Therapy in Clinical Practice.
- Published in:
- International Journal of MS Care, 2020, v. 22, n. S2, p. 3
- By:
- Publication type:
- Article